Back to results
US 12,180,551 B2Granted
Method of using biomarkers and clinical variables for predicting chemotherapy benefit
AssigneeMyriad International GmbH
InventorsAlexander Gutin, Julia Reid, Ralf Kronenwett, Marsel Scheer
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.
Claims20
A method for detecting a responder to chemotherapy comprising:
- (a) measuring RNA expression level values of four or more of the following 8 genes in a tumor sample from a patient suffering from or at risk of developing recurrent neoplastic disease:
- UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST and MGP;
- or
- (b) measuring the RNA expression levels of four or more of the following 8 genes in a tumor sample from the patient:
- UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST and MGP,
- wherein a combined score generated by combining an expression score with a clinical values score is indicative of a prognosis for the patient, and wherein the expression score was generated by combining the expression level values for the genes of the mentioned set recited in (a) or the mentioned set recited in (b).
3 more elements
Dependencies are inferred from the claim text.